Evidence map›Paper›PMID 28894088›Full record

ArticleScientific reports2017

A de novo substructure generation algorithm for identifying the privileged chemical fragments of liver X receptorβ agonists.

He Peng, Zhihong Liu, Xin Yan, Jian Ren, Jun Xu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

He PengResearch Center for Drug Discovery, School of Pharmaceutical Sciences and School of Life Sciences, Sun Yat-Sen University, 132 East Circle at University City, Guangzhou, 510006, China.
Zhihong LiuResearch Center for Drug Discovery, School of Pharmaceutical Sciences and School of Life Sciences, Sun Yat-Sen University, 132 East Circle at University City, Guangzhou, 510006, China.
Xin YanResearch Center for Drug Discovery, School of Pharmaceutical Sciences and School of Life Sciences, Sun Yat-Sen University, 132 East Circle at University City, Guangzhou, 510006, China.
Jian RenResearch Center for Drug Discovery, School of Pharmaceutical Sciences and School of Life Sciences, Sun Yat-Sen University, 132 East Circle at University City, Guangzhou, 510006, China. renjian@mail.sysu.edu.cn.
Jun XuResearch Center for Drug Discovery, School of Pharmaceutical Sciences and School of Life Sciences, Sun Yat-Sen University, 132 East Circle at University City, Guangzhou, 510006, China. junxu9@mail.sysu.edu.cn.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver X receptorβ (LXRβ) is a promising therapeutic target for lipid disorders, atherosclerosis, chronic inflammation, autoimmunity, cancer and neurodegenerative diseases. Druggable LXRβ agonists have been explored over the past decades. However, the pocket of LXRβ ligand-binding domain (LBD) is too large to predict LXRβ agonists with novel scaffolds based on either receptor or agonist structures. In this paper, we report a de novo algorithm which drives privileged LXRβ agonist fragments by starting with individual chemical bonds (de novo) from every molecule in a LXRβ agonist library, growing the bonds into substructures based on the agonist structures with isomorphic and homomorphic restrictions, and electing the privileged fragments from the substructures with a popularity threshold and background chemical and biological knowledge. Using these privileged fragments as queries, we were able to figure out the rules to reconstruct LXRβ agonist molecules from the fragments. The privileged fragments were validated by building regularized logistic regression (RLR) and supporting vector machine (SVM) models as descriptors to predict a LXRβ agonist activities.

Indexed as

AlgorithmsDrug DesignMolecular StructureHumansLigandsLiver X ReceptorsSupport Vector MachineLigandsLiver X Receptors

Identifiers

PMID28894088
PMCPMC5593923
OpenAlexW2752008993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.